Latest Insider Transactions at Immuno Gen, Inc. (IMGN)
This section provides a real-time view of insider transactions for Immuno Gen, Inc. (IMGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ImmunoGen, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ImmunoGen, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 07
2023
|
Richard John Wallace Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$140,000
$14.7 P/Share
|
|
Nov 06
2023
|
Renee Lentini VP & PRIN ACCTG OFFICER |
SELL
Open market or private sale
|
Direct |
219,545
-100.0%
|
$3,293,175
$15.29 P/Share
|
|
Nov 06
2023
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
120,528
+8.91%
|
$843,696
$7.05 P/Share
|
|
Oct 30
2023
|
Mark Alan Goldberg Director |
SELL
Exercise of conversion of derivative security
|
Direct |
10,000
-14.26%
|
$150,000
$15.08 P/Share
|
|
Oct 30
2023
|
Mark Alan Goldberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.48%
|
$140,000
$14.7 P/Share
|
|
Oct 16
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
192,004
-98.56%
|
$2,688,056
$14.4 P/Share
|
|
Oct 16
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
192,004
+32.09%
|
$768,016
$4.55 P/Share
|
|
Sep 29
2023
|
Mark Alan Goldberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,063
+1.74%
|
$15,945
$15.87 P/Share
|
|
Sep 29
2023
|
Stuart A Arbuckle Director |
BUY
Grant, award, or other acquisition
|
Direct |
827
+14.34%
|
$12,405
$15.87 P/Share
|
|
Sep 29
2023
|
Helen M. Thackray Director |
BUY
Grant, award, or other acquisition
|
Direct |
472
+14.33%
|
$7,080
$15.87 P/Share
|
|
Sep 22
2023
|
Dean J Mitchell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.15%
|
$140,000
$14.7 P/Share
|
|
Sep 15
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
192,013
-98.56%
|
$2,880,195
$15.44 P/Share
|
|
Sep 15
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
108,668
+18.27%
|
$326,004
$3.43 P/Share
|
|
Sep 13
2023
|
Stephen C Mccluski Director |
SELL
Exercise of conversion of derivative security
|
Direct |
10,000
-100.0%
|
$160,000
$16.05 P/Share
|
|
Sep 13
2023
|
Stephen C Mccluski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$140,000
$14.7 P/Share
|
|
Sep 13
2023
|
Kristine Peterson Director |
SELL
Exercise of conversion of derivative security
|
Direct |
10,000
-100.0%
|
$160,000
$16.08 P/Share
|
|
Sep 13
2023
|
Kristine Peterson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$140,000
$14.7 P/Share
|
|
Sep 12
2023
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,141
+8.31%
|
$100,564
$4.28 P/Share
|
|
Sep 08
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
26,006
+41.3%
|
$182,042
$7.69 P/Share
|
|
Aug 09
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
100,210
-90.14%
|
$1,402,940
$14.2 P/Share
|
|
Aug 09
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
100,210
+47.41%
|
$400,840
$4.92 P/Share
|
|
Aug 04
2023
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
992,397
-64.21%
|
$15,878,352
$16.96 P/Share
|
|
Aug 04
2023
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,104,218
+18.99%
|
$5,521,090
$5.15 P/Share
|
|
Aug 04
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
80,326
-87.99%
|
$1,365,542
$17.05 P/Share
|
|
Aug 04
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
80,326
+46.81%
|
$321,304
$4.92 P/Share
|
|
Aug 03
2023
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,020,000
-69.79%
|
$16,320,000
$16.61 P/Share
|
|
Aug 03
2023
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,020,000
+20.83%
|
$4,080,000
$4.9 P/Share
|
|
Aug 03
2023
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
51,033
+22.88%
|
$102,066
$2.49 P/Share
|
|
Aug 02
2023
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
995,157
-35.29%
|
$16,917,669
$17.8 P/Share
|
|
Aug 02
2023
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
995,157
+40.92%
|
$3,980,628
$4.55 P/Share
|
|
Aug 02
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,255
-27.97%
|
$76,590
$18.12 P/Share
|
|
Aug 02
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,255
+21.85%
|
$17,020
$4.92 P/Share
|
|
Aug 02
2023
|
Renee Lentini VP & PRIN ACCTG OFFICER |
SELL
Open market or private sale
|
Direct |
148,277
-86.65%
|
$2,520,709
$17.55 P/Share
|
|
Aug 02
2023
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
148,277
+23.33%
|
$593,108
$4.88 P/Share
|
|
Jun 30
2023
|
Stuart A Arbuckle Director |
BUY
Grant, award, or other acquisition
|
Direct |
695
+14.46%
|
$12,510
$18.87 P/Share
|
|
Jun 30
2023
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,195
+12.27%
|
$12,780
$4.05 P/Share
|
|
Jun 30
2023
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,792
+25.71%
|
$15,168
$4.05 P/Share
|
|
Jun 30
2023
|
Anna Berkenblit SVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,264
+2.79%
|
$13,056
$4.05 P/Share
|
|
Jun 30
2023
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
2,811
+3.16%
|
$11,244
$4.05 P/Share
|
|
Jun 30
2023
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,241
+1.17%
|
$20,964
$4.05 P/Share
|
|
Jun 30
2023
|
Helen M. Thackray Director |
BUY
Grant, award, or other acquisition
|
Direct |
397
+14.45%
|
$7,146
$18.87 P/Share
|
|
Jun 30
2023
|
Mark Alan Goldberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
894
+1.49%
|
$16,092
$18.87 P/Share
|
|
Mar 31
2023
|
Mark Alan Goldberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,394
+7.02%
|
$13,182
$3.84 P/Share
|
|
Mar 31
2023
|
Stuart A Arbuckle Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,417
+50.0%
|
$10,251
$3.84 P/Share
|
|
Mar 31
2023
|
Helen M. Thackray Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,953
+50.0%
|
$5,859
$3.84 P/Share
|
|
Dec 30
2022
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,351
+6.43%
|
$4,053
$3.92 P/Share
|
|
Dec 30
2022
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
1,131
+1.34%
|
$3,393
$3.92 P/Share
|
|
Dec 30
2022
|
Anna Berkenblit SVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
436
+0.39%
|
$1,308
$3.92 P/Share
|
|
Nov 15
2022
|
Kristen Harrington Smith SVP & CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
-
|
|
Jun 30
2022
|
Anna Berkenblit SVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,073
+2.71%
|
$9,219
$3.83 P/Share
|